SCHEMBL237269

SCHEMBL237269

CC(C)(C)c1ccc(N2[C@H](c3ccc(Br)cc3)CC[C@H]2c2ccc(Br)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 2/20 0.45
CYP3A4 P08684 5/20 0.44
CYP2C9 P11712 5/20 0.44
CYP2C19 P33261 5/20 0.44
MAPK1 P28482 2/20 0.44
TSHR P16473 2/20 0.44
ALOX15 P16050 2/20 0.44
LMNA P02545 1/20 0.44
ALDH1A1 P00352 4/20 0.42
PDE5A O76074 1/20 0.41
RIPK1 Q13546 1/20 0.38
CYP2D6 P10635 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
GALR3 O60755 1/20 0.36
MITF O75030 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240803 1.00 PRKCZ (0.45) PRKCZCYP3A4CYP2C9CYP2C19MAPK1
SCHEMBL240802 1.00 PRKCZ (0.45) PRKCZCYP3A4CYP2C9CYP2C19MAPK1
SCHEMBL1982892 0.87 HSD11B1 (0.48) CYP3A4CYP2C9CYP2C19MAPK1TSHR
SCHEMBL1982836 0.86 PRKCZ (0.42) PRKCZCYP3A4CYP2C9CYP2C19MAPK1
SCHEMBL1989822 0.84 RIPK1 (0.38) PRKCZCYP3A4CYP2C9CYP2C19MAPK1
SCHEMBL1989823 0.84 MAPT (0.43) PRKCZCYP3A4CYP2C19MAPK1LMNA
SCHEMBL1989751 0.84 MAPT (0.43) PRKCZCYP3A4CYP2C19MAPK1LMNA
SCHEMBL2374410 0.84 RIPK1 (0.38) PRKCZCYP3A4CYP2C9CYP2C19MAPK1
SCHEMBL14856415 0.84 MAPT (0.43) PRKCZCYP3A4CYP2C19MAPK1LMNA
SCHEMBL6123402 0.84 CYP3A4 (0.41) PRKCZCYP3A4CYP2C9CYP2C19MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
CN-115403652-A Preparation method of obitasvir 心远(广州)药物研究有限公司 2022-11-29 CN disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 US disclosed
US-20170157104-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
US-20170157105-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
EP-2678334-B1 ANTI-VIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2017-03-22 EP disclosed
US-9586978-B2 Anti-viral compounds ABBVIE INC. (US) 2017-03-07 US disclosed
EP-2368890-B1 Hepatitis C virus inhibitors ABBVIE BAHAMAS LTD (BS) 2013-04-17 EP disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 US disclosed
EP-2455376-A1 Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) Abbott Laboratories (US) 2012-05-23 EP disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 US disclosed
EP-2368890-A1 Hepatitis C virus inhibitors Abbott Laboratories (US) 2011-09-28 EP disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed
EP-2337781-A2 ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION Abbott Laboratories (US) 2011-06-29 EP disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 US disclosed
US-20100317568-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-12-16 US disclosed
WO-2010144646-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317568-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-20170157105-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-20170157104-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS PRKCZ 3226/4885CYP3A4 1792/4885CYP2C9 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.